AC Immune SA
Change company Symbol lookup
Select an option...
ACIU AC Immune SA
KPRX Kiora Pharmaceuticals Inc
ATIF ATIF Holdings Ltd
BHR Braemar Hotels & Resorts Inc
QTEKW QualTek Services Equity Warrant Exp 14th Feb 2027 *W EXP 02/14/2027
ALR Alerislife Inc
CCEP Coca-Cola Europacific Partners PLC
QQQ Invesco QQQ Trust
BARK Bark Inc
DTM DT Midstream Inc
Go

Health Care : Biotechnology | Small Cap Value
Based in Switzerland
Company profile

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Closing Price
$3.33
Day's Change
-0.14 (-4.03%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.55
Day's Low
3.32
Volume
(Below Average)
Volume:
30,849

10-day average volume:
36,211
30,849

Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference

8:00 am ET July 28, 2022 (BusinessWire) Print

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)" is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference being held at the InterContinental Boston Hotel on August 8-11, 2022.

Mr. Drysdale's fireside chat will be webcast live on Thursday, August 11, 2022 at 3:30 p.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company's investor relations website on the Events & Presentations page.

About Cybin

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005365/en/

SOURCE: Cybin Inc.

Investor & Media: 
Leah Gibson
Vice President, Investor Relations & Strategic Communications
Cybin Inc.
irteam@cybin.com - or - media@cybin.com
comtex tracking

COMTEX_411155480/1006/2022-07-28T08:00:14

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.